Peo in Interest of Trujillo

CourtColorado Court of Appeals
DecidedDecember 31, 2025
Docket25CA1938
StatusUnpublished

This text of Peo in Interest of Trujillo (Peo in Interest of Trujillo) is published on Counsel Stack Legal Research, covering Colorado Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Peo in Interest of Trujillo, (Colo. Ct. App. 2025).

Opinion

25CA1938 Peo in Interest of Trujillo 12-31-2025

COLORADO COURT OF APPEALS

Court of Appeals No. 25CA1938 Arapahoe County District Court No. 25MH452 Honorable H. Clay Hurst, Judge

The People of the State of Colorado,

Petitioner-Appellee,

In the Interest of Deanna Marie Trujillo,

Respondent-Appellant.

ORDER AFFIRMED

Division I Opinion by JUDGE SCHUTZ J. Jones and Grove, JJ., concur

NOT PUBLISHED PURSUANT TO C.A.R. 35(e) Announced December 31, 2025

Ron Carl, County Attorney, Meghan Rubincam, Senior Assistant County Attorney, Arapahoe, Colorado for Petitioner-Appellee

Tezak Law, P.C., Mary Tezak, Florence, Colorado, for Respondent-Appellant ¶1 Deanna Marie Trujillo appeals the district court’s order

(1) certifying her for short-term mental health treatment and

(2) authorizing the administration of medications to her without her

consent. She contends that the evidence was insufficient to sustain

either portion of the order. We disagree and therefore affirm.

I. Background

¶2 Trujillo was admitted to the Colorado Mental Health Hospital

in Pueblo (the hospital) in April 2024 after being found incompetent

to proceed in a criminal case. Her symptoms included being manic,

psychotic, and delusional, and hearing the voices of, and talking to,

people who were not there.

¶3 In July 2025, Trujillo was found to be permanently

incompetent to proceed and her criminal case was dismissed.

Trujillo’s psychiatrist at the hospital then filed a short-term

certification to continue her treatment. The psychiatrist also filed

an affidavit explaining Trujillo’s diagnosis of bipolar disorder and

her need for medications.

¶4 Soon thereafter, Trujillo and the State filed a stipulation

agreeing to the certification (to expire in October 2025) and that

1 Trujillo would take two antipsychotic medications and a mood-

stabilizing medication.

¶5 In September 2025, after Trujillo had been transferred to the

hospital’s geriatric unit, Trujillo’s psychiatrist in that unit, Dr.

Charles Dygert, filed an extended certification for short-term

treatment seeking to continue Trujillo’s treatment for an additional

three months. Dr. Dygert also filed an affidavit requesting

authorization to treat Trujillo with four antipsychotic medications —

Fanapt (iloperidone), Latuda (lurasidone), Invega Sustenna

(paliperidone palmitate), and Prolixin (fluphenazine) — and to

continue her on the mood-stabilizing medication lithium.

¶6 This time, Trujillo, through her appointed counsel, requested a

hearing. Dr. Dygert and Trujillo testified at the hearing.

¶7 Dr. Dygert, whom the parties stipulated was an expert in

psychiatry, testified that Trujillo’s specific diagnosis is type I bipolar

disorder with psychosis, with type I being a classic bipolar disorder

with episodes of “full mania,” as well as major depression. Dr.

Dygert opined that Trujillo is gravely disabled due to the disorder.

¶8 In terms of the medications, Dr. Dygert testified that Trujillo

was taking the maximum dose of Saphris — which had not been

2 effective for her symptoms — Latuda, and lithium. Dr. Dygert

contemplated the following treatment plan:

• Discontinue the use of Saphris and start using Fanapt,

which is “a more consistently successful antipsychotic.”

Depending on the effectiveness of Fanapt, Trujillo would

take either only Fanapt or both Fanapt and Latuda.

• If taking both Fanapt and Latuda proved ineffective, he

would administer Invega Sustenna, which proved

effective for her in the recent past but was stopped

because she complained of its side effects.

• The fourth antipsychotic, Prolixin by injection, would be

used solely if Trujillo refuses other medications orally.

• Trujillo would continue taking lithium, which is “a very

well-established treatment for bipolar, especially type I

bipolar disorder,” in combination with one or more

antipsychotics.

¶9 Dr. Dygert testified that Trujillo does not have insight into her

mental illness and, although she was taking her medications

voluntarily, she stated that she would stop taking them after being

discharged from the hospital. Dr. Dygert testified that, without the

3 medications, Trujillo would experience a significant deterioration of

her condition, both in terms of the severity and frequency of her

symptoms. Finally, Dr. Dygert testified that when Trujillo is ready

to be discharged, it will likely be to a structured facility such as

assisted living or a nursing home.

¶ 10 During Trujillo’s testimony, when her counsel asked her

whether she has a mental illness, she responded, “I believe I have a

mental illness to a — to a point. I think that they’re extending it

out a little farther than . . . what it is.” But her counsel then asked

her whether she has bipolar, and she responded, “Well, my

grandfather when I was younger put me on this computer system,

and when I was on the computer system . . . I had visions, and I

had . . . visuals that were really cool.” Trujillo then testified that

she was off the computer system for a number of years, but then

she “was able to stream back into the computer. But since then I’ve

had somebody tamper with it, and now it’s not the same.” She

clarified that she wanted the court to deny the extended

certification, while noting that she would be willing to take Fanapt,

Latuda, and lithium, but did not want to take Invega Sustenna

because of its side effects.

4 ¶ 11 Trujillo also expressed dissatisfaction with having gained 100

pounds during her hospital stay but said that occurred because of

how much she was eating, which is a “part of life here.” Finally, in

terms of her plans following discharge, she testified about her three

possible options for where to live, and that she will have Medicaid

and supplemental security income.

¶ 12 In its oral ruling, the district court specifically credited Dr.

Dygert’s testimony, while also noting that “some of [Trujillo’s]

testimony was clear . . . [b]ut some was a little confusing.” The

court then approved the extended certification for short-term

treatment based in part on its finding that Trujillo is gravely

disabled due to her type I bipolar disorder with psychosis. See

§ 27-65-109(1)(a), C.R.S. 2025. And, after analyzing the four-

element test from People v. Medina, 705 P.2d 961, 973 (Colo. 1985),

the court denied the State’s request to treat Trujillo involuntarily

with Invega Sustenna but granted its request to treat her

involuntarily with Fanapt, Latuda, Prolixin, and lithium.

II. Standards of Review

¶ 13 On a challenge to the sufficiency of the evidence, we review the

record de novo to determine whether the evidence, viewed as a

5 whole and in the light most favorable to the People, is sufficient to

support the district court’s order. People in Interest of Ramsey,

2023 COA 95, ¶ 23. We review de novo the court’s conclusions of

law and defer to the court’s findings of fact if sufficient evidence in

the record supports them. Id. The resolution of conflicts in

testimony and determinations of witness credibility are solely within

the province of the fact finder. Id.

III.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

People v. Medina
705 P.2d 961 (Supreme Court of Colorado, 1985)
People v. Pflugbeil
834 P.2d 843 (Colorado Court of Appeals, 1992)
People ex rel. R.K.L
2016 COA 84 (Colorado Court of Appeals, 2016)
People ex rel. Strodtman
293 P.3d 123 (Colorado Court of Appeals, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
Peo in Interest of Trujillo, Counsel Stack Legal Research, https://law.counselstack.com/opinion/peo-in-interest-of-trujillo-coloctapp-2025.